Recent Press ReleasesApply03.04.2021Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference03.03.2021U.S. FDA Expands Approval of Pfizer’s LORBRENA® as First-Line Treatment for ALK-Positive Metastatic Lung Cancer02.26.2021European Medicines Agency Accepts Pfizer’s Marketing Authorization Application for Its Investigational 20-valent Pneumococcal Conjugate Vaccine for Adults 18 Years of Age or Older02.26.2021EMA Accepts Marketing Application for Somatrogon to Treat Pediatric Patients with Growth Hormone Deficiency02.25.2021Pfizer and BioNTech Initiate a Study as Part of Broad Development Plan to Evaluate COVID-19 Booster and New Vaccine Variants02.23.2021U.S. FDA Accepts for Priority Review Pfizer’s Application for TicoVac™ (Tick-borne Encephalitis Vaccine)02.22.2021Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference02.19.2021Pfizer and BioNTech Submit COVID-19 Vaccine Stability Data at Standard Freezer Temperature to the U.S. FDA02.18.2021Pfizer and BioNTech Commence Global Clinical Trial to Evaluate COVID-19 Vaccine in Pregnant Women02.17.2021Myovant Sciences and Pfizer Announce Publication in the New England Journal of Medicine of Phase 3 LIBERTY Studies of Once-Daily Relugolix Combination Therapy in Women with Uterine FibroidsMedia ContactsGet to Know UsCompany Fact SheetFeatured StoriesPodcastsPress Kits @Pfizer @Pfizer_Newsby pfizerTweets by pfizer_news
